NextCure, Inc. (NXTC) Earnings History
Net Loss9 years of earnings data (2017–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
NextCure, Inc. (NXTC) Earnings Overview
As of October 3, 2026, NextCure, Inc. (NXTC) reported trailing twelve-month net income of -$43M, reflecting +17.7% year-over-year growth. The company earned $-8.05 per diluted share over the past four quarters.
Looking at the long-term picture, NXTC's historical earnings data spans multiple years. The company achieved its highest annual net income of -$15M in fiscal 2017.
NextCure, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including FATE (-$126M net income, -2051.1% margin), RCUS (-$452M net income, -142.9% margin), AGEN ($93M net income, 0.1% margin), NXTC has comparable earnings metrics. Compare NXTC vs FATE →
NXTC Earnings vs Peers
Earnings metrics vs comparable public companies
NXTC Historical Earnings Data (2017–2025)
9 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$56M | -0.3% | -$58M | $-19.65 | - | - |
| 2024 | -$56M | +11.3% | -$60M | $-23.88 | - | - |
| 2023 | -$63M | +16.1% | -$68M | $-27.04 | - | - |
| 2022 | -$75M | -7.7% | -$76M | $-32.32 | - | - |
| 2021 | -$69M | -89.6% | -$71M | $-30.15 | - | - |
| 2020 | -$37M | -8.5% | -$41M | $-15.95 | -163.6% | -184.2% |
| 2019 | -$34M | -48.0% | -$37M | $-25.79 | -531.5% | -590.5% |
| 2018 | -$23M | -47.4% | -$23M | $-12.04 | - | - |
| 2017 | -$15M | - | -$16M | $-8.17 | - | - |
Download Data
Export NXTC earnings history in CSV or JSON format
Free sign-in required to download data
NXTC Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
NXTC — Frequently Asked Questions
Quick answers to the most common questions about buying NXTC stock.
What is NXTC earnings per share (EPS)?
NXTC trailing twelve-month (TTM) diluted EPS is $-8.05, reflecting +17.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2017 to 2025 is available in the table on this page.
What is NextCure, Inc.'s net income?
NextCure, Inc. (NXTC) trailing twelve-month net income is $-43M as of 2025. Earnings grew +17.7% year-over-year.
Is NXTC profitable?
NXTC is not currently profitable on a TTM basis, reporting a net loss of $-43M. Net margin is N/A. Investors should monitor for a return to profitability.
What is NXTC's earnings growth rate?
NXTC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2017 to 2025.
What are NXTC's profit margins?
NextCure, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -111.2%.
Is NXTC growing earnings?
Yes, NXTC earnings are accelerating — EPS growth of +17.7% exceeds the 5-year CAGR of N/A. TTM net income reached $-43M. Earnings momentum is strengthening.
What was NXTC's best earnings year?
NextCure, Inc.'s highest annual net income on record is $-15M, achieved in fiscal year 2017. Earnings history on this page spans 2017 to 2025 and includes all annual and quarterly figures.
What were NXTC's earnings last quarter?
NXTC's most recent reported quarter was Q2 2026. Net income was $-15M with diluted EPS of $-2.80. For a full breakdown of all quarters, see the quarterly earnings table on this page.